Yann Mazabraud - 14 Apr 2023 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
EVP, Head of International
Signature
/s/ Hunter Smith, Attorney-in-Fact for Yann Mazabraud
Issuer symbol
RYTM
Transactions as of
14 Apr 2023
Net transactions value
$0
Form type
4
Filing time
18 Apr 2023, 17:16:15 UTC
Previous filing
16 Feb 2023
Next filing
13 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Restricted Stock Units Disposed to Issuer $0 -41,500 -100% $0.000000* 0 14 Apr 2023 Common Stock 41,500 Direct F1, F2, F3
transaction RYTM Restricted Stock Units Award $0 +41,500 $0.000000 41,500 14 Apr 2023 Common Stock 41,500 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The restricted stock units were rescinded and cancelled by mutual agreement of the reporting person and Issuer. The reporting person received French-qualified restricted stock units on April 14, 2023 as consideration for the recission and cancellation of the restricted stock previously received on February 1, 2023.
F3 The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date.
F4 The restricted stock units vest as to 25% of the total shares on each of April 14, 2024, April 14, 2025, April 14, 2026 and April 14, 2027. The restricted stock units have no expiration date.